West Pharma (WST) Tops Q4 EPS by 10c; misses on guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts WST Hot Sheet
Price: $394.03 +0.14%
EPS Growth %: +12.2%
Financial Fact:
Selling, general and administrative expenses: 58.3M
Today's EPS Names:
ORPB, PBCO, SICP, More
EPS Growth %: +12.2%
Financial Fact:
Selling, general and administrative expenses: 58.3M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
West Pharma (NYSE: WST) reported Q4 EPS of $1.82, $0.10 better than the analyst estimate of $1.72. Revenue for the quarter came in at $748.8 million versus the consensus estimate of $740.75 million.
GUIDANCE:
West Pharma sees FY2025 EPS of $6.00-$6.20, versus the consensus of $7.43. West Pharma sees FY2025 revenue of $2.875-2.905 billion, versus the consensus of $3.04 billion.
For earnings history and earnings-related data on West Pharma (WST) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- Chemung Financial (CHMG) Tops Q3 EPS by 69c
- First Bank (FRBA) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
